Journal of the American Academy of Dermatology
Volume 53, Issue 6 , Pages 966-972 , December 2005

Nonsteroidal anti-inflammatory drugs and the risk of actinic keratoses and squamous cell cancers of the skin

,Accepted 11 May 2005.

References 

  1. Flower R. What are all the things that aspirin does?. BMJ. 2003;327:572–573
  2. Fosslien E. Molecular pathology of cyclooxygenase-2 in neoplasia. Ann Clin Lab Sci. 2000;30:3–21
  3. Buckman SY, Gresham A, Hale P, Hruza G, Anast J, Masferrer J, et al. COX-2 expression is induced by UVB exposure in human skin: implications for the development of skin cancer. Carcinogenesis. 1998;19:723–729
  4. Muller-Decker K, Reinerth G, Krieg P, Zimmermann R, Heise H, Bayerl C, et al. Prostaglandin-H-synthase isozyme expression in normal and neoplastic human skin. Int J Cancer. 1999;82:648–656
  5. Fischer SM, Lo HH, Gordon GB, Seibert K, Kelloff G, Lubet RA, et al. Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, and indomethacin against ultraviolet light-induced skin carcinogenesis. Mol Carcinog. 1999;25:231–240
  6. Asgari M, White E, Chren M-M. Nonsteroidal anti-inflammatory drug use in the prevention and treatment of squamous cell carcinoma. Dermatol Surg. 2004;30:1335–1342
  7. Green A, Williams G, Neale R, Hart V, Leslie D, Parsons P, et al. Daily sunscreen application and betacarotene supplementation in prevention of basal-cell and squamous-cell carcinomas of the skin: a randomised controlled trial. Lancet. 1999;354:723–729
  8. Green A, Beardmore G, Hart V, Leslie D, Marks R, Staines D. Skin cancer in a Queensland population. J Am Acad Dermatol. 1988;19:1045–1052
  9. Green A, Battistutta D, Hart V, Leslie D, Marks G, Williams G, et al. The Nambour Skin Cancer and Actinic Eye Disease Prevention Trial: design and baseline characteristics of participants. Control Clin Trials. 1994;15:512–522
  10. Harris RE, Chlebowski RT, Jackson RD, Frid DJ, Ascenseo JL, Anderson G, et al. Breast cancer and nonsteroidal anti-inflammatory drugs: prospective results from the Women's Health Initiative. Cancer Res. 2003;63:6096–6101
  11. Diepgen TL, Mahler V. The epidemiology of skin cancer. Br J Dermatol. 2002;146(Suppl 61):1–6
  12. Housman TS, Feldman SR, Williford PM, Fleischer AB, Goldman ND, Acostamadiedo JM, et al. Skin cancer is among the most costly of all cancers to treat for the Medicare population. J Am Acad Dermatol. 2003;48:425–429
  13. Mathers C, Penm R, Sanson-Fisher R, Carter R, Campbell E. Health system costs of cancer in Australia 1993-94: an analysis of costs, service use, incidence and mortality by type of cancer. Canberra: Australian Institute of Health and Welfare and National Cancer Control Initiative; 1998;
  14. Alam M, Ratner D. Cutaneous squamous-cell carcinoma. N Engl J Med. 2001;344:975–983
  15. Dore JF, Pedeux R, Boniol M, Chignol MC, Autier P. Intermediate-effect biomarkers in prevention of skin cancer. IARC Sci Publ. 2001;154:81–91
  16. Rivers JK, Arlette J, Shear N, Guenther L, Carey W, Poulin Y. Topical treatment of actinic keratoses with 3.0% diclofenac in 2.5% hyaluronan gel. Br J Dermatol. 2002;146:94–100
  17. Britt H, Miller G, Knox S, Charles J, Valenti L, Henderson J, et al. General practice activity in Australia 2002-03. (General Practice Series No. 14). Canberra: Australian Institute of Health and Welfare; 2003;
  18. Wang JJ, Mitchell P, Smith W, Gillies M, Billson F. Systemic use of anti-inflammatory medications and age-related maculopathy: the Blue Mountains Eye Study. Ophthalmic Epidemiol. 2003;10:37–48
  19. Australian Bureau of Statistics. National Health Survey: Use of Medications, Australia 1995. Canberra: Australian Bureau of Statistics; 1999;
  20. English DR, Armstrong BK, Kricker A, Winter MG, Heenan PJ, Randell PL. Demographic characteristics, pigmentary and cutaneous risk factors for squamous cell carcinoma of the skin: a case-control study. Int J Cancer. 1998;76:628–634
  21. Wilgus TA, Koki AT, Zweifel BS, Kusewitt DF, Rubal PA, Oberyszyn TM. Inhibition of cutaneous ultraviolet light B-mediated inflammation and tumor formation with topical celecoxib treatment. Mol Carcinog. 2003;38:49–58
  22. Arber N, DuBois RN. Nonsteroidal anti-inflammatory drugs and prevention of colorectal cancer. Curr Gastroenterol Rep. 1999;1:441–448
  23. Denkert C, Kobel M, Berger S, Siegert A, Leclere A, Trefzer U, et al. Expression of cyclooxygenase 2 in human malignant melanoma. Cancer Res. 2001;61:303–308
  24. Davies G, Martin LA, Sacks N, Dowsett M. Cyclooxygenase-2 (COX-2), aromatase and breast cancer: a possible role for COX-2 inhibitors in breast cancer chemoprevention. Ann Oncol. 2002;13:669–678
  25. Wolf JE, Taylor JR, Tschen E, Kang S. Topical 3.0% diclofenac in 2.5% hyaluronan gel in the treatment of actinic keratoses. Int J Dermatol. 2001;40:709–713
  26. Rivers JK, McLean DI. An open study to assess the efficacy and safety of topical 3% diclofenac in a 2.5% hyaluronic acid gel for the treatment of actinic keratoses. Arch Dermatol. 1997;133:1239–1242
  27. Nelson C, Rigel D, Smith S, Swanson N, Wolf J. Phase IV, open-label assessment of the treatment of actinic keratosis with 3.0% diclofenac sodium topical gel (Solaraze). J Drugs Dermatol. 2004;3:401–407
  28. Gebauer K, Brown P, Varigos G. Topical diclofenac in hyaluronan gel for the treatment of solar keratoses. Australas J Dermatol. 2003;44:40–43
  29. Friis S, Sorensen HT, McLaughlin JK, Johnsen SP, Blot WJ, Olsen JH. A population-based cohort study of the risk of colorectal and other cancers among users of low-dose aspirin. Br J Cancer. 2003;88:684–688
  30. Sorensen HT, Friis S, Norgard B, Mellemkjaer L, Blot WJ, McLaughlin JK, et al. Risk of cancer in a large cohort of nonaspirin NSAID users: a population-based study. Br J Cancer. 2003;88:1687–1692

 Funding sources: The Nambour Skin Cancer Prevention Trial and follow-up studies have been funded by the National Health and Medical Research Council of Australia. Dr Butler was supported by a Queensland Cancer Fund Clinical Research Fellowship. Dr Neale is a Sidney Sax Fellow and Dr Whiteman is a Senior Research Fellow, both of the National Health and Medical Research Council of Australia.Conflicts of interest: None identified.

PII: S0190-9622(05)02381-9

doi: 10.1016/j.jaad.2005.05.049

Journal of the American Academy of Dermatology
Volume 53, Issue 6 , Pages 966-972 , December 2005

Article Tools